Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - enema - mesalazine 1 g - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; methacrylic acid copolymer; hypromellose; purified talc; colloidal anhydrous silica; iron oxide red; povidone; titanium dioxide; triethyl citrate; ammonia; magnesium stearate; pregelatinised maize starch - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: povidone; magnesium stearate; titanium dioxide; hypromellose; colloidal anhydrous silica; triethyl citrate; purified talc; iron oxide red; microcrystalline cellulose; methacrylic acid copolymer; pregelatinised maize starch; ammonia - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: purified talc; titanium dioxide; microcrystalline cellulose; povidone; methacrylic acid copolymer; iron oxide red; hypromellose; ammonia; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; triethyl citrate; titanium dioxide; povidone; pregelatinised maize starch; methacrylic acid copolymer; microcrystalline cellulose; hypromellose; magnesium stearate; iron oxide red; ammonia; purified talc - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: triethyl citrate; titanium dioxide; magnesium stearate; hypromellose; macrogol 6000; silicon dioxide; iron oxide red; purified talc; sodium starch glycollate type a; carmellose sodium; microcrystalline cellulose; methacrylic acid copolymer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Israel - English - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 400 mg - mesalazine - " ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes."

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

international pharmaceutical services sa-nv - mesalazine 250 mg - gastro-resistant tablet - 250 mg - mesalazine 250 mg - mesalazine